Clinical significance of long noncoding RNA MNX1-AS1 in human cancers: a meta-analysis of cohort studies and bioinformatics analysis based on TCGA datasets

Figures & data

Figure 1. Flow diagram of searching and selecting eligible studies

Table 1. The main characteristics of included cohort studies

Study	Year	Country	Cancer type	Sample size	Detection method	Cutoff value	Survival outcome	Hazard ratios (95% CI)	Analysis type	NOS score
Zhang, W	2019	China	Gastric cancer	96	qRT-PCR	Median expression	OS	2.375 (1.839–3.236)	Multivariate	7
Ma, JX	2019	China	Gastric cancer	52	qRT-PCR	Median expression	OS	1.43 (1.06–1.94)	Survival curve	6
Shuai, Y	2020	China	Gastric cancer	174	qRT-PCR	Median expression	OS DFS	2.5 (1.370–4.61) 2.26 (1.317–3.89)	Multivariate	7
Li, AH	2017	China	Ovarian cancer	177	qRT-PCR	Median expression	OS	2.62 (1.193–4.228)	Multivariate	6
Liu, X	2018	China	Cervical cancer	54	qRT-PCR	Mean expression	OS	2.53 (1.07–5.97)	Survival curve	6
Li, JH	2020	China	Breast cancer	95	ISH	Median score	OS DFS	2.261 (1.017–5.027) 2.215 (1.171–4.190)	Multivariate	6
Yang, RH	2018	China	Lung cancer	124	qRT-PCR	Mean expression	OS	2.578 (1.687–3.941)	Multivariate	7
Liu, HB	2018	China	Lung cancer	43	qRT-PCR	Mean expression	OS	2.41 (1.03–5.65)	Survival curve	6
Liu, GF	2019	China	Lung cancer	116	qRT-PCR	Median expression	OS	2.68 (1.49–4.82)	Survival curve	6
Ji, DG	2019	China	Hepatocellular carcinoma	81	qRT-PCR	Median expression	OS	1.55 (1.20–2.01)	Survival curve	6

Figure 2. Forest plot illustrated the prognostic significance of MNX1-AS1 level for overall survival (a) and disease-free survival (b)

Table 2. The correlation between clinicopathological characteristics and MNX1-AS1 expression

Clinical characteristics	No. of studies	Estimate OR (95%CI)	P value	Heterogeneity
				I^2	P value
Age (≤50 vs. >50)	6	1.26(0.91–1.72)	0.16	0%	0.74
Gender (Male vs. Female)	5	1.02(0.71–1.47)	0.89	0%	0.63
Tumor stage (III–IV vs. I–II)	6	5.21(2.39–11.63)	<0.0001	77%	<0.001
Invasion depth (T3-4 vs. T1-2)	3	3.00(1.31–6.86)	=0.009	67%	0.05
Lymphatic metastasis (+ vs. -)	6	3.70(2.07–6.61)	<0.0001	57%	0.04
Distant metastasis (+ vs. -)	4	3.99(2.41–6.60)	<0.0001	51%	0.11
Tumor differentiation (Poor vs. Moderate/Well)	5	1.62(1.15–2.28)	=0.006	45%	0.12

Figure 3. Forest plot illustrated the associations of MNX1-AS1 level with tumor TNM stage (a) and invasion depth (b)

Figure 4. Forest plot illustrated the associations of MNX1-AS1 level with lymphatic metastasis (a), distant metastasis (b) and tumor differentiation (c)

Figure 5. Kaplan-Meier survival curves generated from Gene Expression Profiling Interactive Analysis (GEPIA) illustrated the prognostic significance of MNX1-AS1 level for overall survival (a) and disease-free survival (b) in cancers

Figure 6. Sensitivity analysis for the pooled estimation of MNX1-AS1 level and OS in cancers